Creative Medical Technology Reports No Revenue and Increased Losses in Q3 2025

Creative Medical Technology Holdings, Inc. reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a continued trend of operational losses and minimal revenue generation. The company recorded no revenue for the three-month period ending September 30, 2025, consistent with the same period in 2024. For the nine-month period, revenue totaled $3,000, a significant decline from $8,000 in the prior year. The gross profit for the nine months was $1,800, down from $4,800 in the same period last year. The operating loss for the third quarter was $1,273,034, compared to a loss of $1,109,674 in the previous year, while the nine-month operating loss increased to $4,197,032 from $3,858,127.

The company's financial position showed a decrease in total assets, which fell to $5,853,003 as of September 30, 2025, from $6,669,143 at the end of 2024. Current assets also declined, primarily due to a reduction in cash and inventory. Cash reserves decreased to $5,375,511 from $5,940,402, while inventory dropped to $994 from $2,194. On the liabilities side, total liabilities remained stable at $261,353, down from $327,644, reflecting a decrease in accounts payable and accrued expenses.

Strategically, Creative Medical Technology has focused on advancing its clinical programs, particularly in the fields of immunotherapy and regenerative medicine. The company has made significant strides in its AlloStem™ and ImmCelz™ platforms, with ongoing clinical trials for treatments targeting chronic lower back pain and Type 1 diabetes. The company reported that patient recruitment for the AlloStemSpine® Chronic Lower Back Pain trial is progressing, and it has received FDA clearance to initiate a Phase I/II clinical trial for the treatment of Type 1 diabetes. These developments are expected to enhance the company's product pipeline and potentially lead to future revenue generation.

Operationally, the company has seen fluctuations in its expenses, with total operating expenses for the nine months rising to $4,198,832, compared to $3,862,927 in the previous year. This increase was driven by higher selling, general, and administrative expenses, which rose by 30% to $2,396,735, largely due to increased marketing and compensation costs. Research and development expenses decreased by 11% to $1,709,719, reflecting a reduction in general research costs and expenses related to the Type I diabetes clinical trial.

Looking ahead, Creative Medical Technology Holdings, Inc. remains focused on its clinical development efforts and aims to leverage its innovative therapies to capture market share in the biotechnology sector. The company has indicated that it will continue to seek strategic partnerships and funding opportunities to support its growth initiatives. However, the ongoing operational losses and limited revenue generation present challenges that the company will need to address as it moves forward.